Efficacy and toxicity of extended aromatase inhibitors after adjuvant aromatase inhibitors-containing therapy for hormone-receptor-positive breast cancer: a literature-based meta-analysis of randomized trials
- 4 Downloads
Endocrine therapy with aromatase inhibitors (AIs) is the cornerstone of adjuvant systemic treatment for postmenopausal patients with hormone receptor-positive breast cancer. It has become clear that hormone receptor-positive breast cancer carries a consistent risk of relapse up to 15 years after diagnosis. Extended duration of adjuvant AIs therapy after completing initial standard adjuvant AIs-containing therapy may prevent late recurrence and death. We performed a meta-analysis to assess the real impact of the extended adjuvant therapy with AIs.
A literature-based meta-analysis of the randomized controlled trials (RCTs) was undertaken. Relevant publications from PubMed, Embase, Cochrane Library, and abstracts from American Society of Clinical Oncology (ASCO) and San Antonio Breast Cancer (SABCS) symposia were searched. The endpoints were disease-free survival (DFS), overall survival (OS), local recurrence, distant recurrence, contralateral breast cancer, non-breast cancer-related death, and toxicity.
Eight trials comprising 15,966 patients met the inclusion criteria. The pooled analysis revealed a significant improvement in DFS (RR = 0.79; 95% CI 0.68–0.91), distant recurrence (RR = 0.75; 95% CI 0.58–0.96), and contralateral breast cancer (RR = 0.53; 95% CI 0.40–0.70) in the extended AIs group. While there was not significant improvement in OS (RR = 1.00, 95% CI 0.99–1.01), non-breast cancer-related death (RR = 1.16, 95% CI 0.96–1.41), and local recurrence (RR = 0.82; 95% CI 0.64–1.06), the subgroup analysis showed that the patient with tumor size > 2 cm (HR = 0.74, RD = − 0.31, P = 0.05 vs. HR = 0.85, RD = − 0.16, P = 0.20), node positive status (HR = 0.77, RD = − 0.27, P = < 0.0001 vs. HR = 0.89, RD = −0.12, P = 0.19) and previous chemotherapy use (HR = 0.75, RD = − 0.29, P = 0.003 vs. HR = 0.91, RD = −0.10, P = 0.44) would get a greater DFS benefit with extended AIs. Longer treatment with AIs was associated with an increased risk ratio of bone pain (RR = 1.26, RD = 0.04, P = 0.003), bone fractures (RR = 1.59, RD = 0.02, P = 0.002), osteoporosis (RR = 1.53, RD = 0.07, P = 0.005), myalgia (RR = 1.26, RD = 0.04, P = 0.02), and treatment discontinuation for adverse events (RR = 1.51, RD = 0.06, P = 0.0009).
After initial standard AIs-containing adjuvant therapy, extended AIs therapy could further bring a DFS benefit for postmenopausal patients with early breast cancer, especially in the patients with high-risk characteristics.
KeywordsBreast cancer Hormone-positive Adjuvant endocrine therapy Aromatase inhibitors Extended adjuvant AIs therapy
Randomized controlled trials
American Society of Clinical Oncology
San Antonio Breast Cancer
Node positive or negative
Contralateral breast cancer
Non-breast cancer-related death
Ovarian function suppression
We thank Luping chen for her support and guidance throughout the project.
W Ding designed the study and developed the analysis plan. W Ding and X.Y. Qian analyzed the data and performed meta-analysis. Z.A. Li and X.Y. Qian assessed the risk of bias. X.Y. Qian contributed in writing of the article. C.J. Tu and G.D. Ruanuan revised the manuscript and polished the language.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no competing interests.
This article does not contain any studies with human participants or animals performed by any of the authors. Ethical approval was not applicable for this systematic review and meta-analysis.
Informed consent was obtained from all individual participants included in the study.
- 9.Gray RG, Rea D, Handley K et al (2013) aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol 31(Supplement 1):18Google Scholar
- 13.Gnant M, Steger G, Greil R et al (2018) A prospective randomized multi-center phase-III trial of additional 2 versus additional 5 years of anastrozole after initial 5 years of adjuvant endocrine therapy—results from 3,484 postmenopausal women in the ABCSG-16 trial. Cancer Res 78(4 Supplement):1Google Scholar
- 15.Ohtani S, Lijima K, Higaki K et al (2019) A prospective randomized multi-center open-label phase III trial of extending aromatase-inhibitor adjuvant therapy to 10 years-Results from 1697 postmenopausal women in the N-SAS BC 05 trial: Arimidex extended adjuvant randomized study (AERAS). Cancer Res 79(4 Supplement):1Google Scholar
- 29.Sgroi DC, Sestak I, Cuzick J et al (2013) Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol 14:1067–1076CrossRefGoogle Scholar
- 30.Gnant M, Filipits M, Greil R et al (2014) Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 risk of recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. Ann Oncol 25:339–345CrossRefGoogle Scholar